^
    Back
    Association details:
    Biomarker:HER-2 positive
    Cancer:HER2 Positive Breast Cancer
    Drug:zanidatamab zovodotin (ZW49) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Ann Oncol
    Title:

    Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers

    Excerpt:
    In a 3+3 design, patients (pts) with HER2+ cancers were dosed with ZW49 IV QW…Overall, the most common histologies were gastric (28%) and breast (22%) cancers...the confirmed objective response rate across multiple cancer types was 28% and disease control rate was 72%....ZW49 has a manageable safety profile with encouraging single-agent antitumor activity in heavily pretreated pts with HER2+ cancers.
    DOI:
    https://doi.org/10.1016/j.annonc.2022.07.589
    Trial ID:
    NCT03821233
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Cancer Res
    Title:

    ZW49, a HER2 targeted biparatopic antibody drug conjugate for the treatment of HER2 expressing cancers

    Excerpt:
    ZW49 is a novel biparatopic HER2-targeted ADC that demonstrated anti-tumor activity in low and high HER2-expressing breast cancer cell lines and PDX models.
    DOI:
    https://doi.org/10.1158/1538-7445.SABCS18-P6-17-13